Pacira BioSciences Settles Patent Disputes, Paves Way for Generic Exparel in 2030

Pacira BioSciences has reached an agreement to settle various patent infringement lawsuits with Fresenius Kabi and other pharmaceutical companies concerning Pacira’s drug, Exparel. Exparel is a long-acting injectable used to manage postsurgical pain effectively. The settlement will allow for a generic version of the painkiller to be introduced by 2030, marking a significant shift in the market landscape for opioid alternatives in postoperative pain management. Details of the agreement signal an end to the ongoing legal disputes surrounding the drug’s patent protections, thereby paving the way for future development and market competition. For further information, visit the article on Law360.